Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
7.61
+0.29 (3.89%)
At close: Jul 10, 2026, 4:00 PM EDT
7.61
0.00 (0.00%)
After-hours: Jul 10, 2026, 4:10 PM EDT
Kyntra Bio Employees
Kyntra Bio had 34 employees as of December 31, 2025. The number of employees decreased by 191 or -84.89% compared to the previous year.
Employees
34
Change (1Y)
-191
Growth (1Y)
-84.89%
Revenue / Employee
$218,794
Profits / Employee
$4,812,206
Market Cap
30.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 34 | -191 | -84.89% |
| Dec 31, 2024 | 225 | -261 | -53.70% |
| Dec 31, 2023 | 486 | -106 | -17.91% |
| Dec 31, 2022 | 592 | 26 | 4.59% |
| Dec 31, 2021 | 566 | -33 | -5.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences Holdings | 39 |
| Plus Therapeutics | 28 |
| Actinium Pharmaceuticals | 25 |
| Daré Bioscience | 24 |
| Lisata Therapeutics | 21 |
| BriaCell Therapeutics | 16 |
| Serina Therapeutics | 16 |
| Tvardi Therapeutics | 12 |
KYNB News
- 4 days ago - Kyntra Bio initiated with an Outperform at Oppenheimer - TheFly
- 4 weeks ago - Kyntra Bio Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Kyntra Bio to present additional MATTERHORN trial data at EHA - TheFly
- 4 weeks ago - Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes - GlobeNewsWire
- 4 weeks ago - Kyntra Bio initiated with a Buy at Rodman & Renshaw - TheFly
- 2 months ago - Kyntra Bio Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - Kyntra Bio Earnings release: Q1 2026 - Filings
- 2 months ago - Kyntra Bio Slides: Q1 2026 - Filings